Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-219C in B Cell-Related Autoimmune Diseases
NCT07507201Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QT-219C in autoimmune disease, systemic lupus erythematosus (SLE), nephrotic syndrome and 3 more, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Incidence of Adverse Events at 90 days and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
QT-219C
03
Conditions
autoimmune diseasesystemic lupus erythematosus (SLE)nephrotic syndromeIgA nephropathy (IgAN)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07507201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507201.